Search

Hydroxyapatite (HA) hybridized poly(N-isopropylacrylamide)-co-acrylic acid (PNIPAM-co-AAc) hydrogel on thermoplastic polyurethane (TPU) were successfully prepared via photocatalytic polymerization technique. Low temperature plasma processing of HMDSZ and O plasma were deposition on substrate. The HA/hydrogel were stabilized by HA of which the wettability was modified by calcium nitrate and ammonium phosphate dibasic. The HA gradually increases with the increase of time cycles. The deposition of organic silicone group by the HMDSZ on the TPU substrate is hydrophobic surface. When deposition of O, the water contact angles (WCA) was changed to <10° and surface hydrophilicity. The materials were characterized by OM, SEM, FT-IR, XPS and XRD. The results showed that the NIPAM: AAc (1:1 mol) polymers possess macropores ranging from 2 to 20 μm, and their large numbers of carboxyl groups and hydroxyl groups result in a favorable adsorption capacity for HA. Swelling studies indicated that NIPAM: AAc (1:1 mol) was 446 ± 0.3%. This work provided a promising alternative method for the fabrication of polymer materials with tunable and interconnected pores structures for the HA. [ABSTRACT FROM AUTHOR]

This study is aimed at comparing the efficacy and safety of loxoprofen sodium hydrogel patch (LX-P) with loxoprofen sodium tablet (LX-T) in patients with knee osteoarthritis (OA). One hundred sixty-nine patients were enrolled in a randomized, controlled, double-blind, double-dummy, multicenter, non-inferiority trial of LX-P. Patients were randomly assigned to either LX-P or LX-T groups for a 4-week treatment. The primary efficacy endpoint was the proportion of patients with an overall improvement of ≥50 %, and the secondary efficacy endpoint was the proportion of patients with an improvement of ≥25 % from baseline in each of the seven main symptoms. The non-inferiority trial was based on a power of 80 % and significance level of 2.5 % with a non-inferiority margin of −10 %. In both intention-to-treat (ITT) and per-protocol (PP) analyses, LX-P was as effective as LX-T in regard to the primary endpoint. In the ITT analysis, the difference between the two groups was 12.6 % [95 % confidence interval, −1.7 to 26.9 %]. No significant differences were found between the two groups in any of the secondary efficacy outcomes. A lower incidence of adverse events was observed in LX-P group; however, the difference was not statistically significant. No serious adverse events were reported in the LX-P group, whereas one case was reported in LX-T group. Based on the present study, topical loxoprofen patch was non-inferior to oral loxoprofen in patients with knee osteoarthritis. [ABSTRACT FROM AUTHOR]